Plasma miR-122 levels in chronic hepatitis C patients achieving sustained virological response following DAA treatment with and without previous anti-miR-122 (RG-101) dosing by van der Ree, M.H, Stelma, F, Willemse, S.B, van der Valk, M, de Vree, J.M.L, Kootstra, N.A, Reesink, H.W

Get full text

No change in hepatitis C virus-specific T cell functionality after successful DAA treatment in chronic hepatitis C patients by Stelma, F, van der Ree, M.H, Sinnige, M.J, Brown, A, Swadling, L, Willemse, S.B, van der Valk, M, de Vree, J.M, Klenerman, P, Barnes, E, Kootstra, N.A, Reesink, H.W

Get full text

Sequence Analysis for Resistance Monitoring following a Single Dose of RG-101, an Anti-MIR Targeting Microrna-122, in Chronic Hepatitis C Patients by van der Ree, M.H, Stelma, F, de Vree, J.M.L, Willemse, S.B, van der Valk, M, van Nuenen, Ad.C, Patick, A, Grint, P, Neben, S, Pavlicek, A, van der Veer, E, Kootstra, N.A, Reesink, H.W

Get full text

A Single Dose of Anti-MIR122 Oligonucleotide RG-101 Results in a less Activated Phenotype of NK Cells in Patients with Chronic Hepatitis C by Stelma, F, van der Ree, M.H, Sinnige, M.J, Marleen de Vree, J, Willemse, S.B, van der Valk, M, Neben, S, Grint, P, Kootstra, N.A, Reesink, H.W

Get full text

P1097 LONG-TERM SAFETY AND EFFICACY OF MIRAVIRSEN IN CHRONIC HEPATITIS C PATIENTS by van der Ree, M.H, van der Meer, A.J, de Bruijne, J, van Vliet, A, Welzel, T.M, Lawitz, E.J, Rodrigues-Torres, M, Kupcova, V, Wiercinska-Drapalo, A, Hodges, M.R, Janssen, H.L.A, Reesink, H.W

Get full text

Provocation testing is irreplaceable to uncover or refute Brugada syndrome – an electrocardiographic validation study during ajmaline provocation by Van Der Ree, M.H, Vendrik, J, Kors, J.A, Wilde, A.A.M, Tan, H.L, Postema, P.G

Get full text

SAT-235 - Plasma miR-122 levels in chronic hepatitis C patients achieving sustained virological response following DAA treatment with and without previous anti-miR-122 (RG-101) dos... by van der Ree, M.H., Stelma, F., Willemse, S.B., van der Valk, M., de Vree, J.M.L., Kootstra, N.A., Reesink, H.W.

Get full text

THU-254 - A Single Dose of Anti-MIR122 Oligonucleotide RG-101 Results in a less Activated Phenotype of NK Cells in Patients with Chronic Hepatitis C by Stelma, F., van der Ree, M.H., Sinnige, M.J., Marleen de Vree, J., Willemse, S.B., van der Valk, M., Neben, S., Grint, P., Kootstra, N.A., Reesink, H.W.

Get full text

THU-324 - No change in hepatitis C virus-specific T cell functionality after successful DAA treatment in chronic hepatitis C patients by Stelma, F., van der Ree, M.H., Sinnige, M.J., Brown, A., Swadling, L., Willemse, S.B., van der Valk, M., de Vree, J.M., Klenerman, P., Barnes, E., Kootstra, N.A., Reesink, H.W.

Get full text

THU-232 - Sequence Analysis for Resistance Monitoring following a Single Dose of RG-101, an Anti-MIR Targeting Microrna-122, in Chronic Hepatitis C Patients by van der Ree, M.H., Stelma, F., de Vree, J.M.L., Willemse, S.B., van der Valk, M., van Nuenen, Ad.C., Patick, A., Grint, P., Neben, S., Pavlicek, A., van der Veer, E., Kootstra, N.A., Reesink, H.W.

Get full text

Is extensive screening for cancer in idiopathic venous thromboembolism warranted? by VAN DOORMAAL, F. F., TERPSTRA, W., VAN DER GRIEND, R., PRINS, M. H., NIJZIEL, M. R., VAN DE REE, M. A., BÜLLER, H. R., DUTILH, J. C., TEN CATE‐HOEK, A., VAN DEN HEILIGENBERG, S. M., VAN DER MEER, J., OTTEN, J. M.

Get full text